In this lab we are implementing a novel technology known as nanomagnetic relaxometry for cancer-related applications - primarily early detection and assessing tumor burden in response to therapy. This technology leverages the different magnetic relaxation properties of biologically targeted iron oxide nanoparticles from those experiencing unrestricted relaxation in the vascular or extracellular spaces. Our initial application using a second–generation MRXTM device is for detecting human ovarian cancer cells in vivo.
After optimizing the in vitro sensitivity, we plan to test the ability of the MRX instrument for detecting ovarian cancer xenografts. We also have the goal of developing sophisticated inverse problem reconstruction techniques that allow for recovery of a high dimensional relaxation field. Finally, we hope to deploy the first human prototype system in our clinics in the next few years.
Weill Cornell Medicine is the biomedical research organization and medical school of Cornell University. The alliance between Senior Scientific and Weill Cornell Medicine represents the company’s third cancer medicine research collaboration. Led at Weill Cornell Medicine by John Babich, PhD, Professor of Radiopharmaceutical Sciences in Radiology, the combined research effort will explore the use of molecularly targeted nanoparticles for non-invasive, non-radioactive detection and diagnosis of prostate cancers.
The UNM Health Sciences Center is the largest academic health complex in the state of New Mexico. Located in Albuquerque, the Health Sciences Center combines 4 mission areas: education, research, patient care, and community outreach.
We have partnered with CINT to develop and optimize nanoparticles for use with our technologies. CINT is affiliated with Sandia and Los Alamos National Laboratories.
The distinguishing characteristic of CINT is its emphasis on exploring the path from scientific discovery to the integration of nanostructures into the micro and macro worlds. This pathway involves the experimental and theoretical exploration of behavior, the development of a wide variety of synthesis and processing approaches, and an understanding of new performance regimes, testing design, and integration of nanoscale materials and structures. Integration itself is key to the exploitation of nanomaterials, and the scientific challenges that it poses are at the heart of the CINT mission.
Through the New Mexico Small Business Assistance (NMSBA )program at Los Alamos National Laboratory (Los Alamos), Senior Scientific worked with Dr. Andrei N. Matlashov, Ph.D., a senior scientist with the Los Alamos SQUID Team. Dr. Matlashov is an expert in the field of Superconducting Quantum Interference Devices (SQUID).
Our company is owned by Manhattan Scientifics, Inc. The MSI business model capitalizes on inventions and technology, from which profits are created through licensing. MSI is dedicated to earning profit for its 8600 shareholders by identifying, supporting, patenting, and marketing technical innovation by harvesting top technology talent to bring game-changing products to the market.
MSI emphasizes novel technology in the nanomedicine space with the potential to be disruptive and the ability to establish sustainable businesses.